Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl H June

Showing results (61-70 of 460) with videos related to

Pageof 46
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|July 19, 2015
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetDavid M Barrett, Stephan A Grupp, Carl H June
The New England Journal of Medicine|January 14, 2016
Chimeric Antigen Receptor T Cells in MyelomaAlfred L Garfall, Edward A Stadtmauer, Carl H June
Immunity|May 26, 2009
Human T regulatory cell therapy: take a billion or so and call me in the morningJames L Riley, Carl H June, Bruce R Blazar
Nature Reviews. Cancer|August 24, 2016
Engineered T cells: the promise and challenges of cancer immunotherapyAndrew D Fesnak, Carl H June, Bruce L Levine
Lancet (London, England)|March 1, 2025
Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cellsDaniel J Baker, Bruce L Levine, Carl H June
Nature Biotechnology|December 11, 2007
Genetic therapies against HIVJohn J Rossi, Carl H June, Donald B Kohn
The Journal of Clinical Investigation|July 19, 2013
Radiation and immunotherapy: a synergistic combinationAnusha Kalbasi, Carl H June, Naomi Haas, et al.
Science Translational Medicine|March 27, 2015
Adoptive cellular therapy: a race to the finish lineCarl H June, Stanley R Riddell, Ton N Schumacher
Nature Medicine|August 5, 2017
Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?Carl H June, Jeremy T Warshauer, Jeffrey A Bluestone
Current Hematologic Malignancy Reports|October 18, 2017
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for CancerNathan Singh, Junwei Shi, Carl H June, et al.
Pageof 46

Showing results (61-70 of 460) with videos related to

Sort By:
Pageof 46
Journal of Immunology (Baltimore, Md. : 1950)|July 19, 2015
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetDavid M Barrett, Stephan A Grupp, Carl H June
The New England Journal of Medicine|January 14, 2016
Chimeric Antigen Receptor T Cells in MyelomaAlfred L Garfall, Edward A Stadtmauer, Carl H June
Immunity|May 26, 2009
Human T regulatory cell therapy: take a billion or so and call me in the morningJames L Riley, Carl H June, Bruce R Blazar
Nature Reviews. Cancer|August 24, 2016
Engineered T cells: the promise and challenges of cancer immunotherapyAndrew D Fesnak, Carl H June, Bruce L Levine
Lancet (London, England)|March 1, 2025
Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cellsDaniel J Baker, Bruce L Levine, Carl H June
Nature Biotechnology|December 11, 2007
Genetic therapies against HIVJohn J Rossi, Carl H June, Donald B Kohn
The Journal of Clinical Investigation|July 19, 2013
Radiation and immunotherapy: a synergistic combinationAnusha Kalbasi, Carl H June, Naomi Haas, et al.
Science Translational Medicine|March 27, 2015
Adoptive cellular therapy: a race to the finish lineCarl H June, Stanley R Riddell, Ton N Schumacher
Nature Medicine|August 5, 2017
Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?Carl H June, Jeremy T Warshauer, Jeffrey A Bluestone
Current Hematologic Malignancy Reports|October 18, 2017
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for CancerNathan Singh, Junwei Shi, Carl H June, et al.
Pageof 46